From October 5 to 7, JSC Grindeks will participate in the international exhibition “CPhI Worldwide 2010” in Paris Nord Villepinte, France. During the exhibition Grindeks will meet with its business partners as well as introduce visitors to its world class services and solutions. Grindeks exhibition stand will be placed in the Hall 5A with number 5H94.
Chairman of the Board of JSC Grindeks Jānis Romanovskis admits: “Grindeks is participating in this exhibition for the third year and has proven itself as a stable player on the global pharmaceutical market. We have many competitive advantages and are able to offer products and services that meet the highest quality requirements for still very reasonable prices. We have gained the reputation of a reliable, stable and qualitative partner! Moreover, participation in the exhibition offers excellent possibility to generate new business alliances, renew existing partnerships, expose new innovations and strengthen the network of a company”.
In its exhibition stand Grindeks will promote cooperation in three main business fields:
1) Research, development, manufacturing and sales of Active pharmaceutical ingredients
2) Full service of contract-manufacturing of final dosage forms (FDF) – development of activities in performing FDF, validation of the manufacturing process and analysis methods, development of drug registration documentation and manufacturing of different technologies of FDF
3) Registration and marketing services including out-licensing, regulatory submissions, marketing authorization, translation, liaison, consulting, readability tests, as well as entire development of drug registration documents inCTD, eCTD in compliance with the EU and CIS countries requirements.
CPhI Worldwide 2010 is the market leading event and will be attended by key professionals from the global pharma community, bringing you face-to face with potential customers old and new.
Grindeks participation in the exhibition is co financed by ERDF.
On Grindeks
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan and the USA. JSC Grindeks shares are listed on the Official List of “Nasdaq OMX Riga”.
Further information:
Laila Klavina
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
e-mail: [email protected]
